Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer

Ann Nucl Med. 2015 Apr;29(3):284-94. doi: 10.1007/s12149-014-0938-2. Epub 2014 Dec 11.

Abstract

Objective: The comparison of 2-deoxy-2-[18F]fluoro-D-glucose (F-18 FDG) and 3'-deoxy-3'-[18F]fluorothymidine (F-18 FLT) imaging in patients with rectal cancer before and after neoadjuvant radiochemotherapy (RCT) in relation to histopathology and immunohistochemistry obtained from surgery.

Methods: 20 consecutive patients (15 m, 5 f), mean age of 65 ± 10 years were included into this prospective study with a mean follow-up of 4.1 ± 0.8 years.

Results: Among histopathological responders (n = 8 out of 20), posttreatment F-18 FLT and F-18 FDG scans were negative in 75 % (n = 6) and 38 % (n = 3), respectively. The mean response index (RI) was 61.0 % ± 14.0 % for F-18 FLT and 58.7 % ± 14.6 % for F-18 FDG imaging. Peritumoral lymphocytic infiltration (CD3 positive cells) was significantly related to posttreatment SUVmax in F-18 FDG but not F-18 FLT studies.

Conclusion: A significant decrease of SUVmax in F-18 FDG and F-18 FLT studies could be seen after RCT. Negative posttreatment F-18 FLT studies identified more histopathological responders.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Chemoradiotherapy
  • Dideoxynucleosides
  • Female
  • Fluorodeoxyglucose F18
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Multimodal Imaging
  • Neoadjuvant Therapy
  • Positron-Emission Tomography* / methods
  • Prospective Studies
  • Radiopharmaceuticals
  • Rectal Neoplasms / diagnostic imaging*
  • Rectal Neoplasms / pathology
  • Rectal Neoplasms / therapy*
  • Tomography, X-Ray Computed* / methods
  • Treatment Outcome

Substances

  • Dideoxynucleosides
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • alovudine